|
Sharmistha Mishra Person1 #679880 Sharmistha Mishra is an infectious disease physician and mathematical modeler and holds a Tier 2 Canadian Research Chair in Mathematical Modeling and Program Science. | 
- Dr. Sharmistha Mishra is an infectious disease physician and mathematical modeler and holds a Tier 2 Canadian Research Chair in Mathematical Modeling and Program Science. After completing medical school and residency training (Internal Medicine, Infectious Diseases) at the University of Toronto, she obtained a Masters of Science degree in epidemiology and a Doctor of Philosophy in mathematical modelling at Imperial College London. She joined St. Michael’s Hospital in September 2014. She was also involved in the 2014-2015 Ebola response in Sierra Leone, as a consultant with the World Health Organization, from December 2014 to July 2015.
|
+Citations (8) - CitationsAdd new citationList by: CiterankMapLink[2] Modelling the impact of extending dose intervals for COVID-19 vaccines in Canada
Author: Austin Nam, Raphael Ximenes, Man Wah Yeung, Sharmistha Mishra, Jianhong Wu, Matthew Tunis, Beate Sander Publication date: 10 April 2021 Publication info: medRxiv 2021.04.07.21255094 Cited by: David Price 10:39 AM 21 October 2022 GMT Citerank: (3) 679757Beate SanderCanada Research Chair in Economics of Infectious Diseases and Director, Health Modeling & Health Economics and Population Health Economics Research at THETA (Toronto Health Economics and Technology Assessment Collaborative).10019D3ABAB, 679812Jianhong WuProfessor Jianhong Wu is a University Distinguished Research Professor and Senior Canada Research Chair in industrial and applied mathematics at York University. He is also the NSERC Industrial Research Chair in vaccine mathematics, modelling, and manufacturing. 10019D3ABAB, 690189Man Wah YeungSenior Health Economist at the Public Health Agency of Canada.10019D3ABAB URL: DOI: https://doi.org/10.1101/2021.04.07.21255094
| Excerpt / Summary Background: Dual dose SARS-CoV-2 vaccines demonstrate high efficacy and will be critical in public health efforts to mitigate the COVID-19 pandemic and its health consequences; however, many jurisdictions face very constrained vaccine supply. We examined the impacts of extending the interval between two doses of mRNA vaccines in Canada in order to inform deliberations of Canada’s National Advisory Committee on Immunization.
Methods: We developed an age-stratified, deterministic, compartmental model of SARS-CoV-2 transmission and disease to reproduce the epidemiologic features of the epidemic in Canada. Simulated vaccination comprised mRNA vaccines with explicit examination of effectiveness against disease (67% [first dose], 94% [second dose]), hospitalization (80% [first dose], 96% [second dose]), and death (85% [first dose], 96% [second dose]) in adults aged 20 years and older. Effectiveness against infection was assumed to be 90% relative to the effectiveness against disease. We used a 6-week mRNA dose interval as our base case (consistent with early program rollout across Canadian and international jurisdictions) and compared extended intervals of 12 weeks, 16 weeks, and 24 weeks. We began vaccinations on January 1, 2021 and simulated a third wave beginning on April 1, 2021.
Results: Extending mRNA dose intervals were projected to result in 12.1-18.9% fewer symptomatic cases, 9.5-13.5% fewer hospitalizations, and 7.5-9.7% fewer deaths in the population over a 12-month time horizon. The largest reductions in hospitalizations and deaths were observed in the longest interval of 24 weeks, though benefits were diminishing as intervals extended. Benefits of extended intervals stemmed largely from the ability to accelerate coverage in individuals aged 20-74 years as older individuals were already prioritized for early vaccination. Conditions under which mRNA dose extensions led to worse outcomes included: first-dose effectiveness < 65% against death; or protection following first dose waning to 0% by month three before the scheduled 2nd dose at 24-weeks. Probabilistic simulations from a range of likely vaccine effectiveness values did not result in worse outcomes with extended intervals.
Conclusion: Under real-world effectiveness conditions, our results support a strategy of extending mRNA dose intervals across all age groups to minimize symptomatic cases, hospitalizations, and deaths while vaccine supply is constrained. |
Link[3] Incidence of SARS-CoV-2 Infection Among People Experiencing Homelessness in Toronto, Canada
Author: Lucie Richard, Rosane Nisenbaum, Michael Brown, Michael Liu, Cheryl Pedersen, Jesse I. R. Jenkinson, Sharmistha Mishra, Stefan Baral, Karen Colwill, Anne-Claude Gingras, Allison McGeer, Stephen W. Hwang Publication date: 13 March 2023 Publication info: JAMA Netw Open. 2023;6(3):e232774 Cited by: David Price 5:57 PM 15 November 2023 GMT Citerank: (2) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 708809Homelessness859FDEF6 URL: DOI: https://doi.org/10.1001/jamanetworkopen.2023.2774
| Excerpt / Summary [JAMA Network Open, 13 March 2023]
Importance: People experiencing homelessness are at high risk of SARS-CoV-2 infection. Incident infection rates have yet to be established in these communities and are needed to inform infection prevention guidance and related interventions.
Objective: To quantify the SARS-CoV-2 incident infection rate among people experiencing homelessness in Toronto, Canada, in 2021 and 2022 and to assess factors associated with incident infection.
Design, Setting, and Participants: This prospective cohort study was conducted among individuals aged 16 years and older who were randomly selected between June and September 2021 from 61 homeless shelters, temporary distancing hotels, and encampments in Toronto, Canada.
Exposures: Self-reported housing characteristics, such as number sharing living space.
Main Outcomes and Measures: Prevalence of prior SARS-CoV-2 infection in summer 2021, defined as self-reported or polymerase chain reaction (PCR)– or serology-confirmed evidence of infection at or before the baseline interview, and SARS-CoV-2 incident infection, defined as self-reported or PCR- or serology-confirmed infection among participants without history of infection at baseline. Factors associated with infection were assessed using modified Poisson regression with generalized estimating equations.
Results: The 736 participants (415 of whom did not have SARS-CoV-2 infection at baseline and were included in the primary analysis) had a mean (SD) age of 46.1 (14.6) years; 486 (66.0%) self-identified as male. Of these, 224 (30.4% [95% CI, 27.4%-34.0%]) had a history of SARS-CoV-2 infection by summer 2021. Of the remaining 415 participants with follow-up, 124 experienced infection within 6 months, representing an incident infection rate of 29.9% (95% CI, 25.7%-34.4%), or 5.8% (95% CI, 4.8%-6.8%) per person-month. Report after onset of the SARS-CoV-2 Omicron variant was associated with incident infection, with an adjusted rate ratio (aRR) of 6.28 (95% CI, 3.94-9.99). Other factors associated with incident infection included recent immigration to Canada (aRR, 2.74 [95% CI, 1.64-4.58]) and alcohol consumption over the past interval (aRR, 1.67 [95% CI, 1.12-2.48]). Self-reported housing characteristics were not significantly associated with incident infection.
Conclusions and Relevance: In this longitudinal study of people experiencing homelessness in Toronto, SARS-CoV-2 incident infection rates were high in 2021 and 2022, particularly once the Omicron variant became dominant in the region. Increased focus on homelessness prevention is needed to more effectively and equitably protect these communities. |
Link[4] Clinical Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Relative to Delta in British Columbia, Canada: A Retrospective Analysis of Whole-Genome Sequenced Cases
Author: Sean P Harrigan, James Wilton, Mei Chong, Younathan Abdia, Hector Velasquez Garcia, Caren Rose, Marsha Taylor, Sharmistha Mishra, Beate Sander, Linda Hoang, John Tyson, Mel Krajden, Natalie Prystajecky, Naveed Z Janjua, Hind Sbihi Publication date: 30 August 2022 Publication info: Clinical Infectious Diseases, Volume 76, Issue 3, 1 February 2023, Pages e18–e25 Cited by: David Price 8:30 PM 26 November 2023 GMT Citerank: (4) 679757Beate SanderCanada Research Chair in Economics of Infectious Diseases and Director, Health Modeling & Health Economics and Population Health Economics Research at THETA (Toronto Health Economics and Technology Assessment Collaborative).10019D3ABAB, 679854Natalie Anne PrystajeckyNatalie Prystajecky is the program head for the Environmental Microbiology program at the BCCDC Public Health Laboratory. She is also a clinical associate professor in the Department of Pathology & Laboratory Medicine at UBC.10019D3ABAB, 679856Naveed Zafar JanjuaDr. Naveed Zafar Janjua is an epidemiologist and senior scientist at the BC Centre for Disease Control and Clinical Associate Professor at School of Population and Public Health, University of British Columbia. Dr. Janjua is a Medical Doctor (MBBS) with a Masters of Science (MSc) degree in Epidemiology & Biostatistics and Doctorate in Public Health (DrPH). 10019D3ABAB, 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1093/cid/ciac705
| Excerpt / Summary [Clinical Infectious Diseases, 1 February 2023]
Background: In late 2021, the Omicron severe acute respiratory syndrome coronavirus 2 variant emerged and rapidly replaced Delta as the dominant variant. The increased transmissibility of Omicron led to surges in case rates and hospitalizations; however, the true severity of the variant remained unclear. We aimed to provide robust estimates of Omicron severity relative to Delta.
Methods: This retrospective cohort study was conducted with data from the British Columbia COVID-19 Cohort, a large provincial surveillance platform with linkage to administrative datasets. To capture the time of cocirculation with Omicron and Delta, December 2021 was chosen as the study period. Whole-genome sequencing was used to determine Omicron and Delta variants. To assess the severity (hospitalization, intensive care unit [ICU] admission, length of stay), we conducted adjusted Cox proportional hazard models, weighted by inverse probability of treatment weights (IPTW).
Results: The cohort was composed of 13 128 individuals (7729 Omicron and 5399 Delta). There were 419 coronavirus disease 2019 hospitalizations, with 118 (22%) among people diagnosed with Omicron (crude rate = 1.5% Omicron, 5.6% Delta). In multivariable IPTW analysis, Omicron was associated with a 50% lower risk of hospitalization compared with Delta (adjusted hazard ratio [aHR] = 0.50, 95% confidence interval [CI] = 0.43 to 0.59), a 73% lower risk of ICU admission (aHR = 0.27, 95% CI = 0.19 to 0.38), and a 5-day shorter hospital stay (aß = −5.03, 95% CI = −8.01 to −2.05).
Conclusions: Our analysis supports findings from other studies that have demonstrated lower risk of severe outcomes in Omicron-infected individuals relative to Delta. |
Link[5] Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada
Author: Shishi Wu, Yanhong Li, Sharmistha Mishra, Korryn Bodner, Stefan Baral, Jeffrey C. Kwong, Xiaolin Wei Publication date: 28 November 2022 Publication info: International Journal of Infectious Diseases, Volume 127, P69-76, FEBRUARY 2023 Cited by: David Price 9:01 PM 26 November 2023 GMT Citerank: (1) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1016/j.ijid.2022.11.028
| Excerpt / Summary [International Journal of Infectious Diseases, 28 November 2022]
Objectives: We examined the incremental protection and durability of infection-acquired immunity against Omicron infection in individuals with hybrid immunity in Ontario, Canada.
Methods: We followed up 6 million individuals with at least one multiplex reverse transcriptase–polymerase chain reaction test before November 21, 2021, until an Omicron infection. Protection via infection-acquired immunity was assessed by comparing Omicron infection risk between previously infected individuals and those without documented infection under different vaccination scenarios and stratified by time since the last infection or vaccination.
Results: A previous infection was associated with 68% (95% CI 61-73) and 43% (95% CI 27-56) increased protection against Omicron infection in individuals with two and three doses, respectively. Among individuals with two-dose vaccination, the incremental protection of infection-induced immunity decreased from 79% (95% CI 75-81) within 3 months after vaccination or infection to 27% (95% CI 14-37) at 9-11 months. In individuals with three-dose vaccination, it decreased from 57% (95% CI 50-63) within 3 months to 37% (95% CI 19-51) at 3-5 months after vaccination or infection.
Conclusion: Previous SARS-CovV-2 infections provide added cross-variant immunity to vaccination. Given the limited durability of infection-acquired protection in individuals with hybrid immunity, its influence on shield-effects at the population level and reinfection risks at the individual level may be limited. |
Link[6] COVID-19 Cases Among Congregate Care Facility Staff by Neighborhood of Residence and Social and Structural Determinants: Observational Study
Author: Huiting Ma, Kristy C Y Yiu, Sharmistha Mishra, et al. Publication date: 4 October 2022 Publication info: JMIR Public Health Surveill 2022;8(10):e34927 Cited by: David Price 11:00 PM 27 November 2023 GMT Citerank: (1) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.2196/34927
| Excerpt / Summary [JMIR Public Health and Surveillance, 4 October 2022]
Background: Disproportionate risks of COVID-19 in congregate care facilities including long-term care homes, retirement homes, and shelters both affect and are affected by SARS-CoV-2 infections among facility staff. In cities across Canada, there has been a consistent trend of geographic clustering of COVID-19 cases. However, there is limited information on how COVID-19 among facility staff reflects urban neighborhood disparities, particularly when stratified by the social and structural determinants of community-level transmission.
Objective: This study aimed to compare the concentration of cumulative cases by geography and social and structural determinants across 3 mutually exclusive subgroups in the Greater Toronto Area (population: 7.1 million): community, facility staff, and health care workers (HCWs) in other settings.
Methods: We conducted a retrospective, observational study using surveillance data on laboratory-confirmed COVID-19 cases (January 23 to December 13, 2020; prior to vaccination rollout). We derived neighborhood-level social and structural determinants from census data and generated Lorenz curves, Gini coefficients, and the Hoover index to visualize and quantify inequalities in cases.
Results: The hardest-hit neighborhoods (comprising 20% of the population) accounted for 53.87% (44,937/83,419) of community cases, 48.59% (2356/4849) of facility staff cases, and 42.34% (1669/3942) of other HCW cases. Compared with other HCWs, cases among facility staff reflected the distribution of community cases more closely. Cases among facility staff reflected greater social and structural inequalities (larger Gini coefficients) than those of other HCWs across all determinants. Facility staff cases were also more likely than community cases to be concentrated in lower-income neighborhoods (Gini 0.24, 95% CI 0.15-0.38 vs 0.14, 95% CI 0.08-0.21) with a higher household density (Gini 0.23, 95% CI 0.17-0.29 vs 0.17, 95% CI 0.12-0.22) and with a greater proportion working in other essential services (Gini 0.29, 95% CI 0.21-0.40 vs 0.22, 95% CI 0.17-0.28).
Conclusions: COVID-19 cases among facility staff largely reflect neighborhood-level heterogeneity and disparities, even more so than cases among other HCWs. The findings signal the importance of interventions prioritized and tailored to the home geographies of facility staff in addition to workplace measures, including prioritization and reach of vaccination at home (neighborhood level) and at work. |
Link[7] Competing health risks associated with the COVID-19 pandemic and early response: A scoping review
Author: Stefan Baral, Amrita Rao, Jean Olivier Twahirwa Rwema, Carrie Lyons, Muge Cevik, Anna E. Kågesten, Daouda Diouf, Annette H. Sohn, Refilwe Nancy Phaswana-Mafuya, Adeeba Kamarulzaman, Gregorio Millett, Julia L. Marcus, Sharmistha Mishra Publication date: 29 August 2022 Publication info: PLoS ONE 17(8): e0273389 Cited by: David Price 11:37 PM 27 November 2023 GMT Citerank: (1) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0 URL: DOI: https://doi.org/10.1371/journal.pone.0273389
| Excerpt / Summary [PLoS ONE, 29 August 2022]
Background: COVID-19 has rapidly emerged as a global public health threat with infections recorded in nearly every country. Responses to COVID-19 have varied in intensity and breadth, but generally have included domestic and international travel limitations, closure of non-essential businesses, and repurposing of health services. While these interventions have focused on testing, treatment, and mitigation of COVID-19, there have been reports of interruptions to diagnostic, prevention, and treatment services for other public health threats.
Objectives: We conducted a scoping review to characterize the early impact of COVID-19 on HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.
Methods: A scoping literature review was completed using searches of PubMed and preprint servers (medRxiv/bioRxiv) from November 1st, 2019 to October 31st, 2020, using Medical Subject Headings (MeSH) terms related to SARS-CoV-2 or COVID-19 and HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition. Empiric studies reporting original data collection or mathematical models were included, and available data synthesized by region. Studies were excluded if they were not written in English.
Results: A total of 1604 published papers and 205 preprints were retrieved in the search. Overall, 8.0% (129/1604) of published studies and 10.2% (21/205) of preprints met the inclusion criteria and were included in this review: 7.3% (68/931) on HIV, 7.1% (24/339) on tuberculosis, 11.6% (26/224) on malaria, 7.8% (19/183) on sexual and reproductive health, and 9.8% (13/132) on malnutrition. Thematic results were similar across competing health risks, with substantial indirect effects of the COVID-19 pandemic and response on diagnostic, prevention, and treatment services for HIV, tuberculosis, malaria, sexual and reproductive health, and malnutrition.
Discussion: COVID-19 emerged in the context of existing public health threats that result in millions of deaths every year. Thus, effectively responding to COVID-19 while minimizing the negative impacts of COVID-19 necessitates innovation and integration of existing programs that are often siloed across health systems. Inequities have been a consistent driver of existing health threats; COVID-19 has worsened disparities, reinforcing the need for programs that address structural risks. The data reviewed here suggest that effective strengthening of health systems should include investment and planning focused on ensuring the continuity of care for both rapidly emergent and existing public health threats. |
Link[8] Comparison of socio-economic determinants of COVID-19 testing and positivity in Canada: A multi-provincial analysis
Author: Lilia Antonova, Chandy Somayaji, Jillian Cameron, Monica Sirski, Maria E. Sundaram, James Ted McDonald, Sharmistha Mishra, Jeffrey C. Kwong, Alan Katz,Stefan Baral, Lisa Caulley, Andrew Calzavara, Martin Corsten , Stephanie Johnson-Obaseki Publication date: 23 August 2023 Publication info: PLoS ONE 18(8): e0289292. Cited by: David Price 0:23 AM 28 November 2023 GMT Citerank: (2) 701020CANMOD – PublicationsPublications by CANMOD Members144B5ACA0, 703966Social determinants859FDEF6 URL: DOI: https://doi.org/10.1371/journal.pone.0289292
| Excerpt / Summary [PLoS ONE, 23 August 23, 2023]
Background: The effects of the COVID-19 pandemic have been more pronounced for socially disadvantaged populations. We sought to determine how access to SARS-CoV-2 testing and the likelihood of testing positive for COVID-19 were associated with demographic factors, socioeconomic status (SES) and social determinants of health (SDH) in three Canadian provinces.
Methods: An observational population-based cross-sectional study was conducted for the provinces of Ontario, Manitoba and New Brunswick between March 1, 2020 and April 27, 2021, using provincial health administrative data. After excluding residents of long-term care homes, those without current provincial health insurance and those who were tested for COVID-19 out of province, records from provincial healthcare administrative databases were reviewed for 16,900,661 healthcare users. Data was modelled separately for each province in accordance to a prespecified protocol and follow-up consultations among provincial statisticians and collaborators. We employed univariate and multivariate regression models to examine determinants of testing and test results.
Results: After adjustment for other variables, female sex and urban residency were positively associated with testing, while female sex was negatively associated with test positivity. In New Brunswick and Ontario, individuals living in higher income areas were more likely to be tested, whereas in Manitoba higher income was negatively associated with both testing and positivity. High ethnocultural composition was associated with lower testing rates. Both high ethnocultural composition and high situational vulnerability increased the odds of testing positive for SARS-CoV-2.
Discussion: We observed that multiple demographic, income and SDH factors were associated with SARS-CoV-2 testing and test positivity. Barriers to healthcare access identified in this study specifically relate to COVID-19 testing but may reflect broader inequities for certain at-risk groups. |
|
|